Two Sigma Investments LP Sells 227,733 Shares of Cellebrite DI Ltd. (NASDAQ:CLBT)

Two Sigma Investments LP trimmed its stake in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 14.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,349,659 shares of the company's stock after selling 227,733 shares during the period. Two Sigma Investments LP owned 0.66% of Cellebrite DI worth $29,733,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of CLBT. True Wind Capital Management L.P. grew its holdings in Cellebrite DI by 18.2% during the fourth quarter. True Wind Capital Management L.P. now owns 13,861,007 shares of the company's stock valued at $305,358,000 after purchasing an additional 2,130,386 shares during the period. FMR LLC lifted its position in shares of Cellebrite DI by 89.1% during the 4th quarter. FMR LLC now owns 10,621,344 shares of the company's stock valued at $233,988,000 after buying an additional 5,004,587 shares in the last quarter. Axon Enterprise Inc. bought a new position in shares of Cellebrite DI during the 4th quarter valued at approximately $198,270,000. Voss Capital LP increased its holdings in Cellebrite DI by 1.2% in the 4th quarter. Voss Capital LP now owns 3,240,000 shares of the company's stock worth $71,377,000 after acquiring an additional 39,700 shares in the last quarter. Finally, Pertento Partners LLP raised its stake in Cellebrite DI by 26.7% during the 4th quarter. Pertento Partners LLP now owns 2,975,374 shares of the company's stock worth $65,547,000 after acquiring an additional 626,373 shares during the period. 45.88% of the stock is currently owned by hedge funds and other institutional investors.

Cellebrite DI Price Performance

Shares of CLBT stock traded up $0.50 during mid-day trading on Monday, hitting $17.21. The company had a trading volume of 1,554,679 shares, compared to its average volume of 1,462,127. The stock's 50 day moving average price is $18.91 and its 200-day moving average price is $20.20. Cellebrite DI Ltd. has a 52-week low of $10.25 and a 52-week high of $26.30. The company has a market capitalization of $4.12 billion, a P/E ratio of -12.38, a P/E/G ratio of 4.27 and a beta of 1.44.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported $0.10 EPS for the quarter, topping the consensus estimate of $0.09 by $0.01. Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. The business had revenue of $107.55 million for the quarter, compared to analysts' expectations of $109.36 million. During the same quarter in the previous year, the company earned $0.08 EPS. The business's quarterly revenue was up 20.0% compared to the same quarter last year. On average, equities research analysts expect that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.

Wall Street Analysts Forecast Growth

CLBT has been the subject of a number of recent analyst reports. Needham & Company LLC dropped their price target on shares of Cellebrite DI from $28.00 to $24.00 and set a "buy" rating for the company in a research report on Wednesday, May 14th. JPMorgan Chase & Co. dropped their target price on shares of Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating for the company in a report on Monday, May 12th. Finally, Lake Street Capital increased their price target on Cellebrite DI from $17.00 to $26.00 and gave the stock a "buy" rating in a research note on Friday, February 14th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, Cellebrite DI presently has an average rating of "Buy" and a consensus price target of $22.43.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.